Cargando…

The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts

Xpert(®) MTB/RIF has been widely used for tuberculosis (TB) diagnosis in Brazil, since 2014. This prospective observational study aimed to evaluate the performance of Xpert in different contexts during a two-year period: (i) laboratory and clinical/epidemiological diagnosis; (ii) HIV-positive and -n...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomaz, Ana Paula de Oliveira, Raboni, Sonia Mara, Kussen, Gislene Maria Botão, da Silva Nogueira, Keite, Lopes Ribeiro, Clea Elisa, Costa, Libera Maria Dalla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928506/
https://www.ncbi.nlm.nih.gov/pubmed/33657113
http://dx.doi.org/10.1371/journal.pone.0247185
_version_ 1783659871403507712
author Tomaz, Ana Paula de Oliveira
Raboni, Sonia Mara
Kussen, Gislene Maria Botão
da Silva Nogueira, Keite
Lopes Ribeiro, Clea Elisa
Costa, Libera Maria Dalla
author_facet Tomaz, Ana Paula de Oliveira
Raboni, Sonia Mara
Kussen, Gislene Maria Botão
da Silva Nogueira, Keite
Lopes Ribeiro, Clea Elisa
Costa, Libera Maria Dalla
author_sort Tomaz, Ana Paula de Oliveira
collection PubMed
description Xpert(®) MTB/RIF has been widely used for tuberculosis (TB) diagnosis in Brazil, since 2014. This prospective observational study aimed to evaluate the performance of Xpert in different contexts during a two-year period: (i) laboratory and clinical/epidemiological diagnosis; (ii) HIV-positive and -negative populations; (iii) type of specimens: pulmonary and extrapulmonary. Overall, 924 specimens from 743 patients were evaluated. The performance of the assays was evaluated considering culture (Lowenstein Jensen or LJ medium) results and composite reference standard (CRS) classification as gold standard. According to CRS evaluation, 219 cases (29.5%) were classified as positive cases, 157 (21.1%) as ‘possible TB’, and 367 (49.3%) as ‘not TB’. Based on culture, Xpert and AFB smear achieved a sensitivity of 96% and 62%, respectively, while based on CRS, the sensitivities of Xpert, AFB smear, and culture were 40.7%, 20%, and 25%, respectively. The pooled sensitivity and specificity of Xpert were 96% and 94%, respectively. Metric evaluations were similar between pulmonary and extrapulmonary samples against culture, whereas compared to CRS, the sensitivities were 44.6% and 29.3% for the pulmonary and extrapulmonary cases, respectively. The Xpert detected 42/69 (60.9%) patients with confirmed TB and negative culture on LJ medium, and 52/69 (75.4%) patients with negative AFB smear results. There was no significant difference in the diagnostic accuracy based on the types of specimens and population (positive- and negative-HIV). Molecular testing detected 13 cases of TB in culture-negative patients with severe immunosuppression. Resistance to rifampicin was detected in seven samples. Herein, Xpert showed improved detection of pulmonary and extrapulmonary TB cases, both among HIV-positive and -negative patients, even in cases with advanced immunosuppression, thereby performing better than multiple other diagnostic parameters.
format Online
Article
Text
id pubmed-7928506
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-79285062021-03-10 The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts Tomaz, Ana Paula de Oliveira Raboni, Sonia Mara Kussen, Gislene Maria Botão da Silva Nogueira, Keite Lopes Ribeiro, Clea Elisa Costa, Libera Maria Dalla PLoS One Research Article Xpert(®) MTB/RIF has been widely used for tuberculosis (TB) diagnosis in Brazil, since 2014. This prospective observational study aimed to evaluate the performance of Xpert in different contexts during a two-year period: (i) laboratory and clinical/epidemiological diagnosis; (ii) HIV-positive and -negative populations; (iii) type of specimens: pulmonary and extrapulmonary. Overall, 924 specimens from 743 patients were evaluated. The performance of the assays was evaluated considering culture (Lowenstein Jensen or LJ medium) results and composite reference standard (CRS) classification as gold standard. According to CRS evaluation, 219 cases (29.5%) were classified as positive cases, 157 (21.1%) as ‘possible TB’, and 367 (49.3%) as ‘not TB’. Based on culture, Xpert and AFB smear achieved a sensitivity of 96% and 62%, respectively, while based on CRS, the sensitivities of Xpert, AFB smear, and culture were 40.7%, 20%, and 25%, respectively. The pooled sensitivity and specificity of Xpert were 96% and 94%, respectively. Metric evaluations were similar between pulmonary and extrapulmonary samples against culture, whereas compared to CRS, the sensitivities were 44.6% and 29.3% for the pulmonary and extrapulmonary cases, respectively. The Xpert detected 42/69 (60.9%) patients with confirmed TB and negative culture on LJ medium, and 52/69 (75.4%) patients with negative AFB smear results. There was no significant difference in the diagnostic accuracy based on the types of specimens and population (positive- and negative-HIV). Molecular testing detected 13 cases of TB in culture-negative patients with severe immunosuppression. Resistance to rifampicin was detected in seven samples. Herein, Xpert showed improved detection of pulmonary and extrapulmonary TB cases, both among HIV-positive and -negative patients, even in cases with advanced immunosuppression, thereby performing better than multiple other diagnostic parameters. Public Library of Science 2021-03-03 /pmc/articles/PMC7928506/ /pubmed/33657113 http://dx.doi.org/10.1371/journal.pone.0247185 Text en © 2021 Tomaz et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tomaz, Ana Paula de Oliveira
Raboni, Sonia Mara
Kussen, Gislene Maria Botão
da Silva Nogueira, Keite
Lopes Ribeiro, Clea Elisa
Costa, Libera Maria Dalla
The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts
title The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts
title_full The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts
title_fullStr The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts
title_full_unstemmed The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts
title_short The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts
title_sort xpert(®) mtb/rif diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: benefits and experiences over 2 years in different clinical contexts
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928506/
https://www.ncbi.nlm.nih.gov/pubmed/33657113
http://dx.doi.org/10.1371/journal.pone.0247185
work_keys_str_mv AT tomazanapauladeoliveira thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT rabonisoniamara thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT kussengislenemariabotao thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT dasilvanogueirakeite thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT lopesribeirocleaelisa thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT costaliberamariadalla thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT tomazanapauladeoliveira xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT rabonisoniamara xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT kussengislenemariabotao xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT dasilvanogueirakeite xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT lopesribeirocleaelisa xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts
AT costaliberamariadalla xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts